SFI
OPNT

Susquehanna Fundamental Investments’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Susquehanna Fundamental Investments’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,052
Closed -$108K – 1583
2022
Q3 		$108K Buy
+10,052
New +$114K ﹤0.01% 1324

Other funds holding OPNT

WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
NYLIM
New York Life Investment Management New York $14.3B AUM 34.42% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
RA
Ramius Advisors New York $95.2M AUM 7.33% 1-Year Est. Return

Susquehanna Fundamental Investments's OPNT Position: Q4 2022 in Review

Susquehanna Fundamental Investments sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q4 2022, closing a stake of 10,052 shares — an estimated $108K sold.

Susquehanna Fundamental Investments first reported a position in OPNT in Q3 2022 and held it in 1 quarter. The position peaked at $108K in Q3 2022. 37 funds tracked by Wall St. Rank hold OPNT as of Q4 2022.

  • Susquehanna Fundamental Investments reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 10,052 Opiant Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $108K.
  • Susquehanna Fundamental Investments first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $108K in Q3 2022.
  • 37 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2022, filed 14 Feb 2023.